VISEN PHARMA-B repurchases 9,000 shares for HKD 0.21 million; treasury stock rises to 33,200 shares

Bulletin Express05-22

VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed a share buyback on 22 May 2026, acquiring 9,000 ordinary shares on the Hong Kong Stock Exchange and transferring them to treasury stock.

• Transaction details – Repurchase date: 22 May 2026 – Volume: 9,000 shares, representing 0.008 % of the company’s issued share capital (excluding treasury shares) prior to the transaction – Price range: HKD 23.48–24.00 per share – Volume-weighted average price: HKD 23.82 – Total consideration: HKD 0.21 million

• Share-capital impact – Issued shares (excluding treasury shares) decreased to 113.89 million from 113.90 million – Treasury shares increased to 33,200 from 24,200 – Total issued shares remained unchanged at 113.93 million

• Repurchase mandate utilisation – Shareholders approved a mandate on 27 June 2025 authorising the repurchase of up to 11.39 million shares. – Cumulative repurchases under the mandate now stand at 33,200 shares, equal to 0.03 % of the company’s issued shares on the mandate date.

• Post-repurchase restrictions – In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 21 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125621595?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125621595","market":"us","top_or_hot":-1,"title":"VISEN PHARMA-B repurchases 9,000 shares for HKD 0.21 million; treasury stock rises to 33,200 shares","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed a share buyback on 22 May 2026, acquiring 9,000 ordinary shares on the Hong Kong Stock Exchange and transferring them to treasury stock.</p>\n<p>• Transaction details  \n  – Repurchase date: 22 May 2026  \n  – Volume: 9,000 shares, representing 0.008 % of the company’s issued share capital (excluding treasury shares) prior to the transaction  \n  – Price range: HKD 23.48–24.00 per share  \n  – Volume-weighted average price: HKD 23.82  \n  – Total consideration: HKD 0.21 million</p>\n<p>• Share-capital impact  \n  – Issued shares (excluding treasury shares) decreased to 113.89 million from 113.90 million  \n  – Treasury shares increased to 33,200 from 24,200  \n  – Total issued shares remained unchanged at 113.93 million</p>\n<p>• Repurchase mandate utilisation  \n  – Shareholders approved a mandate on 27 June 2025 authorising the repurchase of up to 11.39 million shares.  \n  – Cumulative repurchases under the mandate now stand at 33,200 shares, equal to 0.03 % of the company’s issued shares on the mandate date.</p>\n<p>• Post-repurchase restrictions  \n  – In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 21 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B repurchases 9,000 shares for HKD 0.21 million; treasury stock rises to 33,200 shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B repurchases 9,000 shares for HKD 0.21 million; treasury stock rises to 33,200 shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-22 18:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed a share buyback on 22 May 2026, acquiring 9,000 ordinary shares on the Hong Kong Stock Exchange and transferring them to treasury stock.</p>\n<p>• Transaction details  \n  – Repurchase date: 22 May 2026  \n  – Volume: 9,000 shares, representing 0.008 % of the company’s issued share capital (excluding treasury shares) prior to the transaction  \n  – Price range: HKD 23.48–24.00 per share  \n  – Volume-weighted average price: HKD 23.82  \n  – Total consideration: HKD 0.21 million</p>\n<p>• Share-capital impact  \n  – Issued shares (excluding treasury shares) decreased to 113.89 million from 113.90 million  \n  – Treasury shares increased to 33,200 from 24,200  \n  – Total issued shares remained unchanged at 113.93 million</p>\n<p>• Repurchase mandate utilisation  \n  – Shareholders approved a mandate on 27 June 2025 authorising the repurchase of up to 11.39 million shares.  \n  – Cumulative repurchases under the mandate now stand at 33,200 shares, equal to 0.03 % of the company’s issued shares on the mandate date.</p>\n<p>• Post-repurchase restrictions  \n  – In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 21 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1125621595","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125621595","pubTimestamp":1779445398,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed a share buyback on 22 May 2026, acquiring 9,000 ordinary shares on the Hong Kong Stock Exchange and transferring them to treasury stock. • Transaction...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"维森制药-B以21万港元回购9000股；库存股增至33,200股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals (VISEN PHARMA-B) disclosed a share buyback on 22 May 2026, acquiring 9,000 ordinary shares on the Hong Kong Stock Exchange and transferring them to treasury stock.\n• Transaction details  \n  – Repurchase date: 22 May 2026  \n  – Volume: 9,000 shares, representing 0.008 % of the company’s issued share capital (excluding treasury shares) prior to the transaction  \n  – Price range: HKD 23.48–24.00 per share  \n  – Volume-weighted average price: HKD 23.82  \n  – Total consideration: HKD 0.21 million\n• Share-capital impact  \n  – Issued shares (excluding treasury shares) decreased to 113.89 million from 113.90 million  \n  – Treasury shares increased to 33,200 from 24,200  \n  – Total issued shares remained unchanged at 113.93 million\n• Repurchase mandate utilisation  \n  – Shareholders approved a mandate on 27 June 2025 authorising the repurchase of up to 11.39 million shares.  \n  – Cumulative repurchases under the mandate now stand at 33,200 shares, equal to 0.03 % of the company’s issued shares on the mandate date.\n• Post-repurchase restrictions  \n  – In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 21 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125621595","isCrawlerRequest":true}